- Latest available (Revised)
- Original (As made)
This is the original version (as it was originally made). This item of legislation is currently only available in its original format.
3. In article 4 of the principal Order (medicinal products that are notprescription only), the following paragraph is inserted after paragraph(1C):—
“(1D) Notwithstanding Article 3(1)(a), a medicinal product shall notbe a prescription only medicine by reason that it consists of orcontains the substance Hyoscine Butylbromide where—
(a)its route of administration is internal otherwise than by inhaler;
(b)it is sold or supplied in a container or package containing notmore than 240 mg; and
(c)its container or package is labelled to show a maximum daily doseof 80 mg and a maximum dose of 20 mg.”.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include: